Nuvalent, Inc. is a company specializing in creating precisely targeted therapies for patients with cancer. With deep expertise in chemistry and structure-based drug discovery, Nuvalent is dedicated to developing innovative solutions to combat cancer. They recently announced updated preliminary data from their ALKOVE-1 Trial, which supports their commitment to delivering best-in-class therapies. Additionally, Nuvalent Inc. is holding a $300 million stock offering following promising data from their second lead cancer drug. With a focus on #PreciselyTargetedTherapies, Nuvalent is dedicated to improving the lives of cancer patients.

from ALKOVE-1 Trial that Support Best-In-Class Po... Nuvalent, Inc. announced updated preliminary data ... 󰤥 · 󰤦 · 󰤧.

Nuvalent Inc. is holding a $300 million stock offering just days after it presented promising data from its second lead cancer drug.

Nuvalent, Inc. | 2494 followers on LinkedIn. #PreciselyTargetedTherapies for patients with cancer | Nuvalent is creating precisely targeted ...

Nuvalent, Inc.

Find contacts at this company